The 2 week fasting blood glucose (FBG) level as a predictor of HbA1c treatment response (HbA1c-TR) to once weekly dulaglutide 1.5 mg in patients with type 2 diabetes (T2DM)

Introduction: We assessed whether FBG in patients with T2DM measured early in treatment with the once-weekly GLP-1 receptor agonist dulaglutide 1.5 mg predicts HbA1c-TR. Methods: Post-hoc analyses were conducted for 2 randomized studies in patients assigned to dulaglutide 1.5 mg [AWARD-5 with metformin (N = 304) and AWARD-1 with metformin and pioglitazone). AWARD-5 baseline tertile values were used to categorize FBG at baseline and week 2: low (< 7.9 mmol/l); intermediate (≥7.9 – 10.3 mmol/l); high (≥10.3 mmol/l). AWARD-5 HbA1c-TR was assessed at week 12 and 26 by combined efficacy endpoint (CEE):HbA1c< 7.0% or…